Adolescents and young adults with classical Hodgkin lymphoma in northern Tunisia: insights from an adult single-institutional study.
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bleomycin
/ administration & dosage
Cyclophosphamide
/ administration & dosage
Dacarbazine
/ administration & dosage
Disease-Free Survival
Doxorubicin
/ administration & dosage
Etoposide
/ administration & dosage
Female
Hodgkin Disease
/ epidemiology
Humans
Kaplan-Meier Estimate
Male
Mechlorethamine
/ administration & dosage
Mediastinal Neoplasms
/ pathology
Middle Aged
Organs at Risk
/ radiation effects
Prednisone
/ administration & dosage
Procarbazine
/ administration & dosage
Radiotherapy Dosage
Recurrence
Retrospective Studies
Treatment Outcome
Tunisia
/ epidemiology
Vinblastine
/ administration & dosage
Vincristine
/ administration & dosage
Young Adult
Adolescents
Adolescents and young adults (AYA)
Adolescents et jeunes adultes (AYA)
Adult treatment protocol
Classical Hodgkin lymphoma
Lymphome de Hodgkin classique
Protocole de traitement de l’adulte
Survie
Survival
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
20
11
2019
revised:
27
01
2020
accepted:
30
01
2020
pubmed:
17
3
2020
medline:
18
6
2020
entrez:
16
3
2020
Statut:
ppublish
Résumé
The aim of this study was to extensively describe the epidemiological, clinical and therapeutic outcomes of adolescents and young adults (AYA) population with classical Hodgkin Lymphoma (cHL). Then, a comparison between AYAs and adults and between the subgroups of AYAs treated with the same adult protocol was accomplished to further inform on optimal therapy approach of choice for adolescent patients. In this mono-centric, retrospective study, we reviewed the medical records. We analyzed 112 consecutive North Tunisian patients, including 66 AYAs (15 to 39 years) and 46 adults (≥40years) affected by cHL treated from 2000 to 2015 at Salah Azaiez Institute. Then, we performed a comparative analysis between AYA and 46 adult patients and a subgroup analysis between adolescents and young adults. All patients were treated according to the national protocol for HL, edited by the Tunisian Society of Hematology. The treatment included chemotherapy and involved-field radiotherapy (RT) at a dose of 20 or 30 Grays (Gy) for responders and 36Gy for non-responders. AYA patients presented with adverse features with nodular sclerosis subtype (p=3.88×10 The treatment approach used is well tolerated by adult patients. However, the AYA patients and particularly adolescent subgroup had more advanced disease at diagnosis and should be treated more intensively in dedicated units. RT dose<36Gy and ABVD chemotherapy were associated with lower EFS in this population.
Identifiants
pubmed: 32171674
pii: S1278-3218(20)30049-4
doi: 10.1016/j.canrad.2020.01.004
pii:
doi:
Substances chimiques
Bleomycin
11056-06-7
Procarbazine
35S93Y190K
Mechlorethamine
50D9XSG0VR
Vincristine
5J49Q6B70F
Vinblastine
5V9KLZ54CY
Etoposide
6PLQ3CP4P3
Dacarbazine
7GR28W0FJI
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
206-214Informations de copyright
Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.